Avantor is expected to report Q3 2026 revenue of $1.76 billion and adjusted EPS of $0.21, with the current stock price of $22.45 trading significantly below the average analyst target of $28.50.
Investors are primarily focused on core organic revenue growth, specifically within the bioprocessing segment, to gauge the pace of recovery in the life sciences end market.
After several quarters of headwinds from inventory destocking, analysts are looking for stabilization in order patterns and signs that recent cost-reduction initiatives are effectively protecting operating margins. Management’s updated commentary on the 2027 demand outlook will be critical for sentiment given recent volatility in global laboratory spending.